Literature DB >> 8154880

Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons.

G R Uhl1, D Walther, D Mash, B Faucheux, F Javoy-Agid.   

Abstract

Dopamine transporter messenger RNA (mRNA) expression was assessed by in situ hybridization over individual pigmented neurons from the substantia nigra pars compacta in midbrain sections from 7 parkinsonian and 7 age-matched, neurologically normal patients. In the normal control brains, high levels of expression of dopamine transporter mRNA were noted over pigmented neurons in the substantia nigra pars compacta; neurons in the adjacent nucleus paranigralis of the ventral tegmental area displayed less hybridization. Nigra compacta neurons surviving in brains of patients with Parkinson's disease displayed only 57% of the dopamine transporter mRNA hybridization intensity displayed by nigral neurons in normal control brains. The disease-related decrease in the apparent level of dopamine transporter mRNA expression in remaining neurons could reflect neuronal dysfunction. Conceivably, it might also reflect differential vulnerability of those neurons that initially expressed higher levels of this transporter to the insult of parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8154880     DOI: 10.1002/ana.410350421

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  26 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens.

Authors:  M J Nirenberg; J Chan; A Pohorille; R A Vaughan; G R Uhl; M J Kuhar; V M Pickel
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

3.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.

Authors:  N Takahashi; L L Miner; I Sora; H Ujike; R S Revay; V Kostic; V Jackson-Lewis; S Przedborski; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

4.  The neuronal monoamine transporter VMAT2 is regulated by the trimeric GTPase Go(2).

Authors:  M Höltje; B von Jagow; I Pahner; M Lautenschlager; H Hörtnagl; B Nürnberg; R Jahn; G Ahnert-Hilger
Journal:  J Neurosci       Date:  2000-03-15       Impact factor: 6.167

5.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

Authors:  Chee Yeun Chung; Hyemyung Seo; Kai Christian Sonntag; Andrew Brooks; Ling Lin; Ole Isacson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

Review 6.  Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission.

Authors:  S Chalon; S Vancassel; L Zimmer; D Guilloteau; G Durand
Journal:  Lipids       Date:  2001-09       Impact factor: 1.880

7.  Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.

Authors:  T J Counihan; J B Penney
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

8.  Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons.

Authors:  Dong-Youn Hwang; Sunghoi Hong; Joo-Won Jeong; Sangdun Choi; Hansoo Kim; Jangwoo Kim; Kwang-Soo Kim
Journal:  J Neurochem       Date:  2009-09-24       Impact factor: 5.372

Review 9.  Parkinson's disease: is the initial treatment established?

Authors:  J Eric Ahlskog
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

10.  Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease.

Authors:  Tomás González-Hernández; Ignacio Cruz-Muros; Domingo Afonso-Oramas; Josmar Salas-Hernandez; Javier Castro-Hernandez
Journal:  Front Neuroanat       Date:  2010-10-20       Impact factor: 3.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.